trending Market Intelligence /marketintelligence/en/news-insights/trending/yqdojkdaxau2rttgvbn-va2 content esgSubNav
In This List

Aileron Therapeutics' chief medical, scientific officer becomes CEO

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Aileron Therapeutics' chief medical, scientific officer becomes CEO

Aileron Therapeutics Inc. appointed Manuel Aivado as president and CEO.

Aivado succeeds John Longenecker, who replaced Joseph Yanchik III on an interim basis after he resigned.

Aivado has been the senior vice president and chief medical and scientific officer of the biopharmaceutical company since 2012. He most recently designed and implemented the first-in-human trial of the company's experimental anti-tumor therapy ALRN-6924.